Skip NavigationSkip to Content
Return Return to Search Results

Temporal Dominance of B.1.1.7 over B.1.354 SARS-CoV-2 Variant: A Hypothesis Based on Areas of Variant Co-Circulation

  1. Author:
    Kostaki, Evangelia Georgia
    Tseti, Ioulia
    Tsiodras, Sotirios
    Pavlakis,George
    Sfikakis, Petros P.
    Paraskevis, Dimitrios

  2. Author Address

    Natl & Kapodistrian Univ Athens, Med Sch, Dept Hyg Epidemiol & Med Stat, Athens 11527, Greece.Uni Pharma SA, Kifisia 14564, Greece.Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Med Sch, Dept Internal Med 4, Haidari 12462, Greece.NCI, Human Retrovirus Sect, Frederick, MD 21702 USA.Natl & Kapodistrian Univ Athens, Med Sch, Dept Prop Internal Med 1, Athens 11527, Greece.
    1. Year: 2021
    2. Date: May
    3. Epub Date: 2021 04 22
  2. Journal: Life (Basel, Switzerland)
  3. MDPI,
    1. 11
    2. 5
  5. Type of Article: Article
  6. Article Number: 375
  7. ISSN: 2075-1729
  1. Abstract:

    Some emergent SARS-CoV-2 variants raise concerns due to their altered biological properties. For both B.1.1.7 and B.1351 variants, named as variants of concern (VOC), increased transmissibility was reported, whereas B.1.351 was more resistant to multiple monoclonal antibodies (mAbs), as well as convalescent and vaccination sera. To test this hypothesis, we examined the proportion of VOC over time across different geographic areas where the two VOC, B.1.1.7 and B.1.351, co-circulate. Our comparative analysis was based on the number of SARS-CoV-2 sequences on GISAID database. We report that B.1.1.7 dominates over B.1.351 in geographic areas where both variants co-circulate and the B.1.1.7 was the first variant introduced in the population. The only areas where B.1.351 was detected at higher proportion were South Africa and Mayotte in Africa, where this strain was associated with increased community transmission before the detection of B.1.1.7. The dominance of B.1.1.7 over B.1.351 could be important since B.1.351 was more resistant to certain mAbs, as well as heterologous convalescent and vaccination sera, thus suggesting that it may be transmitted more effectively in people with pre-existing immunity to other VOC. This scenario would lessen the effectiveness of vaccine and urge the need to update them with new strains.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.3390/life11050375
  3. PMID: 33921938
  4. View record in Web of Science®
  5. WOS: 000654134800001

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel